These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12746944)

  • 1. Clinical application of direct sputum sensitivity testing in a severe infective exacerbation of cystic fibrosis.
    Serisier DJ; Jones G; Tuck A; Connett G; Carroll MP
    Pediatr Pulmonol; 2003 Jun; 35(6):463-6. PubMed ID: 12746944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct antimicrobial susceptibility testing method for analysis of sputum collected from patients with cystic fibrosis.
    Zebouh M; Thomas C; Honderlick P; Lemee L; Segonds C; Wallet F; Husson MO
    J Cyst Fibros; 2008 May; 7(3):238-43. PubMed ID: 18498727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
    Bosso JA; Mauldin PD; Steed LL
    Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.
    Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C
    J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective analysis of biofilm antibiotic susceptibility testing: a better predictor of clinical response in cystic fibrosis exacerbations.
    Keays T; Ferris W; Vandemheen KL; Chan F; Yeung SW; Mah TF; Ramotar K; Saginur R; Aaron SD
    J Cyst Fibros; 2009 Mar; 8(2):122-7. PubMed ID: 19064337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing.
    Foweraker JE; Laughton CR; Brown DF; Bilton D
    J Antimicrob Chemother; 2005 Jun; 55(6):921-7. PubMed ID: 15883175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
    Etherington C; Hall M; Conway S; Peckham D; Denton M
    J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'.
    Saiman L
    Paediatr Respir Rev; 2007 Sep; 8(3):249-55. PubMed ID: 17868923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Nocardia farcinica infection in a patient with cystic fibrosis].
    Beucher J; Belleguic C; Brinchault G; Deneuville E; Donnio PY; Roussey M
    Rev Mal Respir; 2010; 27(1):76-9. PubMed ID: 20146956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of a new E-test method for antimicrobial sensitivity testing of Pseudomonas aeruginosa isolates from cystic fibrosis].
    Zebouh M; Thomas C; Honderlick P; Lemee L; Segonds C; Wallet F; Husson MO
    Pathol Biol (Paris); 2005; 53(8-9):490-4. PubMed ID: 16087300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.
    Foweraker JE; Laughton CR; Brown DF; Bilton D
    Antimicrob Agents Chemother; 2009 Nov; 53(11):4809-15. PubMed ID: 19704123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients.
    Worlitzsch D; Rintelen C; Böhm K; Wollschläger B; Merkel N; Borneff-Lipp M; Döring G
    Clin Microbiol Infect; 2009 May; 15(5):454-60. PubMed ID: 19196263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
    Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
    Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis.
    Ferroni A; Guillemot D; Moumile K; Bernede C; Le Bourgeois M; Waernessyckle S; Descamps P; Sermet-Gaudelus I; Lenoir G; Berche P; Taddei F
    Pediatr Pulmonol; 2009 Aug; 44(8):820-5. PubMed ID: 19598278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved early diagnosis of Pseudomonas aeruginosa by real-time PCR to prevent chronic colonisation in a paediatric cystic fibrosis population.
    McCulloch E; Lucas C; Ramage G; Williams C
    J Cyst Fibros; 2011 Jan; 10(1):21-4. PubMed ID: 20920896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis.
    White L; Mirrani G; Grover M; Rollason J; Malin A; Suntharalingam J
    Respir Med; 2012 Mar; 106(3):356-60. PubMed ID: 22204744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis.
    Mirakhur A; Gallagher MJ; Ledson MJ; Hart CA; Walshaw MJ
    J Cyst Fibros; 2003 Mar; 2(1):19-24. PubMed ID: 15463841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Pseudomonas aeruginosa Antibiotic Resistance Genes Varies Greatly during Infections in Cystic Fibrosis Patients.
    Martin LW; Robson CL; Watts AM; Gray AR; Wainwright CE; Bell SC; Ramsay KA; Kidd TJ; Reid DW; Brockway B; Lamont IL
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.